Abstract:Background: High mobility group protein B3 (HMGB3) is abundantly expressed in a number of malignancies, contributing to tumor cell growth and predicting poor outcomes. More research on the connection between HMGB3 and breast cancer is needed. The prognostic significance of HMGB3 in breast cancer was examined and validated in this study. Methods: Using The Cancer Genome Atlas (TCGA) database RNA sequencing and clinical data, we investigated the associations between HMGB3 expression and tumor mutations, prognosis, and immune infiltration in breast cancer. The Gene Expression Profiling Interactive Analysis (GEPIA), Tumor Immune Estimation Resource (TIMER), breast cancer gene-expression miner (bc-GenExMiner), UALCAN, OncoLnc, cBio Cancer Genomics Portal (cBioPortal), and LinkedOmics databases were applied to examine the levels of expression, mutation, coexpression, and immune correlation of HMGB3 in breast cancer. cBioPortal and the Database for Annotation, Visualization, and Integrated Discovery (DAVID) were used for coexpression and enrichment analyses, respectively. Experimental tests and a separate cohort of breast cancer patients in our center were used for validation. To determine independent risk factors affecting breast carcinoma prognosis, multivariate Cox regression analysis was performed. The Kaplan-Meier method was applied to analyze the connection between HMGB3 expression and overall survival time in breast cancer. Results: Pan-cancer investigation using the GEPIA and UALCAN databases revealed a high level of HMGB3 expression in different malignancies, including breast cancer. HMGB3 might be a potential diagnostic biomarker, according to the receiver operating characteristic (ROC) curve (AUC=0.932). And immunohistochemistry confirmed higher HMGB3 protein expression in breast cancer tissues in clinical samples. Experimental tests also showed that breast cancer cells have higher expression of HMGB3, and knockdown of HMGB3 can promote the proliferation of breast cancer cells and increase sensitivity to chemotherapy. Human epidermal growth factor receptor 2 (HER2), Nottingham Prognostic Index (NPI), basal-like status, nodal status (N+), triple-negative status, and Scarff-Bloom-Richardson (SBR) grade all showed positive correlations with HMGB3 expression. Conversely, HMGB3 expression was negatively associated with the expression of estrogen receptor (ER) and progesterone receptor (PR) in breast cancer. Breast cancer patients with high HMGB3 expression had poor overall survival, which was validated by an analysis of a separate cohort of breast cancer patients in our center. Cox regression analysis identified high HMGB3 expression as an independently associated risk factor for breast carcinoma. The amount of immunological infiltration was substantially linked with the high expression of HMGB3. The chromosome centromeric region, ATPase activity, and the cell cycle are critical areas where HMGB3 is involved, according to enrichment analysis. Therefore, we suspected that HMGB3 might be a potential biomarker for detecting and treating breast carcinoma. Conclusion: Breast cancer tissues had higher HMGB3 expression than normal breast tissues. HMGB3 overexpression may serve as an indicator for poor breast cancer outcomes.

High expression of DLG3 is associated with decreased survival from breast cancer.

Dystroglycan is Associated with Tumor Progression and Patient Survival in Gastric Cancer

Biomarker Discovery To Improve Prediction Of Breast Cancer Survival: Using Gene Expression Profiling, Meta-Analysis, And Tissue Validation

High Expression of Lc3b is Associated with Progression and Poor Outcome in Triple-Negative Breast Cancer

Overexpression of Golph3 is Associated with Poor Survival in Non-Small-Cell Lung Cancer

Examination of the Expression and Prognostic Significance of DLGAPs in Gastric Cancer Using the TCGA Database and Bioinformatic Analysis

DNASE1L3 as a Prognostic Biomarker Associated with Immune Cell Infiltration in Cancer

Comprehensive Analysis of PDLIM3 Expression Profile, Prognostic Value, and Correlations with Immune Infiltrates in Gastric Cancer

High Expression of DLL3 is Associated with a Poor Prognosis and Immune Infiltration in Invasive Breast Cancer Patients.

The Significance of Discs Large Homolog 2 Expression in Hepatocellular Carcinoma: A Laboratory Study

DLGAP5 Regulates the Proliferation, Migration, Invasion, and Cell Cycle of Breast Cancer Cells via the JAK2/STAT3 Signaling Axis

Increased expression of mdig predicts poorer survival of the breast cancer patients

Spindle apparatus coiled‐coil protein 1 (SPDL1) serves as a novel prognostic biomarker in triple‐negative breast cancer

Biological and immunological significance of DLL3 expression in different tumor tissues: a pan-cancer analysis

L3MBTL3 is a Potential Prognostic Biomarker and Correlates with Immune Infiltrations in Gastric Cancer

Association of GATA3 expression in triple-positive breast cancer with overall survival and immune cell infiltration

Overexpression of HMGB3 and its prognostic value in breast cancer

43P PDL1 Protein Expression is a Prognostic Factor in Triple Negative Breast Cancer

PBX3-activated DLG1-AS1 Can Promote the Proliferation, Invasion and Migration of TNBC Cells by Sponging Mir-16-5p

Downregulation of DPF3 Promotes the Proliferation and Motility of Breast Cancer Cells Through Activating JAK2/STAT3 Signaling.

High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers